Literature DB >> 8456765

Rapid redistribution of teboroxime.

H Weinstein1, S T Dahlberg, B A McSherry, R C Hendel, J A Leppo.   

Abstract

Teboroxime, a new technetium-99m-labeled myocardial perfusion tracer, possesses rapid myocardial kinetics. Whereas this agent is routinely imaged after separate stress and rest injections, experimental data suggest that teboroxime may rapidly redistribute in the myocardium. Accordingly, we assessed 68 exercise teboroxime scintigrams in which immediate poststress, early delay (5 minutes) and rest images were acquired. Studies were categorized visually as ischemia, infarct or normal based on conventional stress-rest comparison. They were then evaluated for rapid teboroxime redistribution by comparing the stress and early delay images. Quantitative analysis was then performed on 537 myocardial segments. Segments were grouped as ischemia, infarct or normal based on stress-rest comparison, and the degree of normalization of stress-induced defects in the early delay images was determined for each group. Rapid teboroxime redistribution was observed in 20 of 46 scintigrams (48%) considered ischemic, and in 2 of 7 and 2 of 15 scintigrams deemed infarct and normal, respectively. The mean segmental intensity ratio (defined relative to the opposite segment) improved from 0.79 at stress to 0.88 at early delay (p < 0.005) in the group with ischemia and from 0.83 to 0.87 in the group with infarction. The most likely explanation for rapid redistribution of teboroxime is differential washout from the myocardium between areas of disparate flow. It is concluded that rapid redistribution of teboroxime occurs within 5 minutes of a stress injection, giving rise to potentially useful clinical information. Thus, teboroxime imaging should be completed expeditiously to detect areas of relative hypoperfusion.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8456765     DOI: 10.1016/0002-9149(93)90835-z

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  7 in total

1.  Simultaneous assessment of cardiac perfusion and function using 5-dimensional imaging with Tc-99m teboroxime.

Authors:  Bing Feng; P Hendrik Pretorius; Troy H Farncombe; Seth T Dahlberg; Manoj V Narayanan; Miles N Wernick; Anna M Celler; Jeffrey A Leppo; Michael A King
Journal:  J Nucl Cardiol       Date:  2006 May-Jun       Impact factor: 5.952

2.  The effect of ischemic injury on the cardiac transport of Tc-99m N-NOET in the isolated rabbit heart.

Authors:  T A Holly; J A Leppo; M P Gilmore; C P Reinhardt; S T Dahlberg
Journal:  J Nucl Cardiol       Date:  1999 Nov-Dec       Impact factor: 5.952

Review 3.  Myocardial kinetics of radiolabeled perfusion agents: basis for perfusion imaging.

Authors:  S T Dahlberg; J A Leppo
Journal:  J Nucl Cardiol       Date:  1994 Mar-Apr       Impact factor: 5.952

4.  Myocardial technetium 99m-labeled teboroxime clearance derived from canine scans differentiates severity of stenosis after dipyridamole.

Authors:  G Johnson; D K Glover; C B Hebert; R D Okada
Journal:  J Nucl Cardiol       Date:  1994 Jul-Aug       Impact factor: 5.952

Review 5.  Technetium-99m Radiopharmaceuticals for Ideal Myocardial Perfusion Imaging: Lost and Found Opportunities.

Authors:  Alessandra Boschi; Licia Uccelli; Lorenza Marvelli; Corrado Cittanti; Melchiore Giganti; Petra Martini
Journal:  Molecules       Date:  2022-02-10       Impact factor: 4.411

6.  Static Versus Dynamic Teboroxime Myocardial Perfusion SPECT in Canines.

Authors:  D J Kadrmas; E V R Di Bella; H S Khare; P E Christian; G T Gullberg
Journal:  IEEE Trans Nucl Sci       Date:  2000-06-01       Impact factor: 1.679

7.  Myocardial clearance of technetium-99m-teboroxime in reperfused injured canine myocardium.

Authors:  David R Okada; Gerald Johnson; Robert D Okada
Journal:  EJNMMI Res       Date:  2014-08-01       Impact factor: 3.138

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.